2126 — JW (Cayman) Therapeutics Co Income Statement
0.000.00%
Last trade - 00:00- HK$741.70m
- -HK$2.43m
- CNY173.86m
Annual income statement for JW (Cayman) Therapeutics Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 30.8 | 146 | 174 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 9.04 | 58.8 | 88.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 205 | 441 | 790 | 1,002 | 963 |
| Operating Profit | -205 | -441 | -759 | -856 | -790 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -633 | -1,664 | -702 | -846 | -768 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -633 | -1,664 | -702 | -846 | -768 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -633 | -1,664 | -702 | -846 | -768 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -633 | -1,664 | -702 | -846 | -768 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.68 | -12.4 | -1.76 | -2.06 | -1.42 |